Skip to main content

Drug Interactions between Fylnetra and topotecan

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

topotecan pegfilgrastim

Applies to: topotecan and Fylnetra (pegfilgrastim)

ADJUST DOSING INTERVAL: Concomitant administration of colony-stimulating factors with topotecan can prolong the duration of neutropenia. The mechanism of interaction has not been established.

MONITOR: Coadministration with colony-stimulating factors may potentiate the risk of interstitial lung disease (ILD) associated with the use of topotecan. According to the product labeling, risk factors for topotecan-induced ILD include a history of ILD, pulmonary fibrosis, lung cancer, thoracic exposure to radiation, and use of pneumotoxic drugs and/or colony-stimulating factors.

MANAGEMENT: Colony-stimulating factors should not be initiated until 24 hours after completion of a course or cycle of topotecan treatment. Patients should be monitored for pulmonary symptoms indicative of ILD such as cough, fever, dyspnea and/or hypoxia. Topotecan should be discontinued if a new diagnosis of ILD is confirmed.

References (1)
  1. (2001) "Product Information. Hycamtin (topotecan)." SmithKline Beecham

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer